Balanced news tone
News Sentiment
DNLI sentiment intelligence
Denali Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
59 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-0.6% over one week, +18.6% over four weeks, trend active, and materially above fair value.
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-0.6%
Price digesting
Trend fit
Trend active
18.6% over four weeks
Fair value
29.9%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
18
Neutral
35
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan
JP Morgan has set a price target of $29.00 per share for Denali Therapeutics, indicating their valuation of the company's stock. This announcement provides investors with an analyst's perspective on the potential future trading price of Denali Therapeutics.
- Tone
- Positive 65/100
- Event
- Analyst action
- Published
- 14 Jul 2026 02:13
- Source
- Moomoo
Moomoo
Direct company coverage
Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating
Wedbush has increased its price target for Denali Therapeutics (NASDAQ: DNLI) from $20 to $26, while maintaining an Outperform rating on the stock. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 13 Jul 2026 14:10
- Source
- Moomoo
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
GuruFocus
Direct company coverage
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 13 Jul 2026 10:50
- Source
- GuruFocus
Investing.com
Direct company coverage
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating
JPMorgan has resumed coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and a $29 price target, citing its transition to a commercial biotech following the approval of Avlayah. The firm anticipates accelerated approval for DNL126 by late 2027 and highlights a
- Tone
- Positive 81/100
- Event
- Analyst action
- Published
- 13 Jul 2026 08:09
- Source
- Investing.com
Quartr
Direct company coverage
Denali Therapeutics (DNLI) Investor Day 2025 Summary
Denali Therapeutics (DNLI) held its 2025 Investor Day, highlighting an expanded strategic focus beyond neurodegeneration to whole-body biotherapeutics using its Transferrin Receptor-enabled TransportVehicle (TV/Tivi) platform. The company aims for two near-term launches, tivideno
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 10 Jul 2026 17:09
- Source
- Quartr
Sahm
Direct company coverage
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI)
T. Rowe Price Investment Management has disclosed a 10.2% stake in Denali Therapeutics, shortly after the company secured FDA approval for its Hunter syndrome therapy, Avlayah, and sold a Rare Pediatric Disease Priority Review Voucher for $195 million. This institutional interest
- Tone
- Positive 63/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 15:09
- Source
- Sahm
The Manila Times
Direct company coverage
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
Denali Therapeutics will deliver the opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026, with CEO Ryan Watts discussing advancements in treating neurodegenerative diseases, particularly Alzheimer's. The company will highlight its proprieta
- Tone
- Positive 94/100
- Event
- Market update
- Published
- 10 Jul 2026 02:40
- Source
- The Manila Times
Stock Titan
Direct company coverage
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s
Denali Therapeutics (Nasdaq: DNLI) announced that co-founder and CEO Ryan Watts, Ph.D., will deliver the opening plenary address at the Alzheimer’s Association International Conference (AAIC) 2026 in London. He will discuss advancements in neurodegeneration biology, biomarkers, a
- Tone
- Positive 76/100
- Event
- Market update
- Published
- 09 Jul 2026 19:40
- Source
- Stock Titan
Investing.com
Direct company coverage
Denali Therapeutics stock hits 52-week high at $26.95
Denali Therapeutics Inc. (DNLI) stock recently hit a 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, but InvestingPro suggests it might be overvalued. Recent positive news includes the sale of a Rare Pediatric Di
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 09 Jul 2026 14:40
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com
Denali Therapeutics Inc. (DNLI) stock has reached a new 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, with InvestingPro suggesting potential overvaluation. Recent developments include selling a Rare Pediatric D
- Tone
- Positive 93/100
- Event
- Market update
- Published
- 09 Jul 2026 13:42
- Source
- Investing.com Canada
TradingView
Direct company coverage
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics (DNLI) has seen its stock surge 59.4% year-to-date, driven by the FDA approval of Avlayah for Hunter syndrome and investor optimism. The approval establishes Denali as a commercial-stage company and validates its TransportVehicle platform, positioning it for l
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 08 Jul 2026 17:41
- Source
- TradingView
Stock Titan
Direct company coverage
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A
T. Rowe Price Investment Management, Inc. has disclosed a 10.2% stake in Denali Therapeutics (DNLI) through a Schedule 13G/A filing. The filing indicates beneficial ownership of 16,178,963 shares, with T. Rowe Price holding sole voting power for 15,639,355 shares and sole disposi
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 08 Jul 2026 15:41
- Source
- Stock Titan
Finviz
Direct company coverage
DNLI - Denali Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial ratios, volatility metrics, and insider/institutional ownership data. It covers various performance indicators like EPS, sales growth, and
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 18:13
- Source
- Finviz
Sahm
Direct company coverage
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally
Denali Therapeutics (DNLI) has seen a significant rally, with a 30-day return of 32.33% and a one-year return of 75.83%. Despite trading at a discount to the average analyst price target, the company's Price-to-Book ratio of 4.4x (compared to the industry average of 2.8x) suggest
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 06 Jul 2026 01:13
- Source
- Sahm
Finviz
Direct company coverage
DNLI - Denali Therapeutics Inc Latest SEC Filings
This page provides a detailed financial overview and snapshot of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It also lists the company's SEC filings and provides
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 05 Jul 2026 12:42
- Source
- Finviz
Ad-hoc-news.de
Direct company coverage
Denali Therapeutics stock stays focused on pipeline progress.
Denali Therapeutics' stock performance is closely tied to the progress of its neuroscience and lysosomal disease pipeline, with investors monitoring development milestones. The company's focus on transport vehicle technology to cross the blood-brain barrier is central to its drug
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 03 Jul 2026 17:41
- Source
- Ad-hoc-news.de
Barchart.com
Direct company coverage
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK
The Amyotrophic Lateral Sclerosis (ALS) market is projected to expand significantly by 2034, driven by an increasing disease prevalence, advancements in drug development, and growing regulatory support. The market experienced an estimated size of USD 850 million in the United Sta
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 01 Jul 2026 23:10
- Source
- Barchart.com
TradingView
Direct company coverage
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article focuses on the enterprise value to EBIT forward metric for Denali Therapeutics Inc. (NASDAQ: DNLI). It presents financial data related to this specific valuation ratio for the biotechnology company. The content appears to be a stub or a section from a financial data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 23:11
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article provides a financial statistic for Denali Therapeutics Inc. (NASDAQ: DNLI). Specifically, it presents the "Price to sales forward" metric for the company. The content appears to be a snapshot from a financial data platform, likely TradingView, showing overview inform
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 08:10
- Source
- TradingView
TradingView
Direct company coverage
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh
This page displays financial information for Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (BMFBOVESPA:D2NL34), specifically its price-to-sales forward ratio. The content appears to be a financial data presentation page from TradingView, offerin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This page provides financial data, specifically the "Price to earnings forward" for Denali Therapeutics Inc. (NASDAQ: DNLI). It indicates that the company's stock is listed on the Nasdaq Stock Market and that the market was closed at the time of the data query, with no trades hav
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 00:40
- Source
- TradingView
TradingView
Direct company coverage
Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN)
This article provides an overview of Denali Therapeutics Inc. (DUS:4DN) financials, analyst estimates, and historical stock performance. It includes details on revenue, earnings per share, net income, key dates like the next earnings report on July 30, 2026, and a stock forecast
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 21:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI
This article provides the enterprise value to EBITDA forward for Denali Therapeutics Inc. (NASDAQ: DNLI). It appears to be a financial data snippet from TradingView, concentrating solely on this specific financial metric for the biotechnology company. The content confirms that no
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:10
- Source
- TradingView
TradingView
Direct company coverage
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI)
This article provides an overview of Denali Therapeutics Inc. (NASDAQ: DNLI) stock, including current prices, historical performance, analyst forecasts, and financial data. It highlights the company's recent stock growth, market capitalization, and upcoming earnings report date,
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 20:40
- Source
- TradingView
Stock Traders Daily
Direct company coverage
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing
This article analyzes Denali Therapeutics Inc. (DNLI) using AI models to determine its impact on rotational strategy timing. It highlights strong sentiment across all horizons supporting an overweight bias and identifies no resistance levels above the current price, suggesting si
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 25 Jun 2026 20:30
- Source
- Stock Traders Daily
Investing.com
Direct company coverage
Denali Therapeutics options trading jumps to 2,291 contracts
Denali Therapeutics Inc. saw a significant increase in options trading, with 2,291 contracts traded by Thursday afternoon. Call volume heavily outweighed put volume, and the July 17, 2026 $30 call option was particularly active. Coinciding with this, Denali Therapeutics shares ex
- Tone
- Positive 59/100
- Event
- Market update
- Published
- 25 Jun 2026 18:09
- Source
- Investing.com
Zacks
Direct company coverage
Denali to Sell Priority Review Voucher for $195M Cash Boost
- Tone
- Negative 42/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 12:40
- Source
- Zacks
MT Newswires
Direct company coverage
Denali Therapeutics to Sell its Rare Pediatric Disease Priority Review Voucher for $195 Million
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 18 Jun 2026 12:20
- Source
- MT Newswires
Stock Titan
Direct company coverage
Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan